Efficacy

Jyseleca (filgotinib) Efficacy in Rheumatoid Arthritis

Jyseleca, also known as filgotinib, is a medication that has demonstrated efficacy in the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Filgotinib is a selective Janus kinase (JAK) inhibitor that targets JAK1, which plays a role in the inflammatory process of RA. Clinical trials have shown that Jyseleca can significantly reduce the signs and symptoms of RA, improve physical function, and inhibit the progression of structural damage as evidenced by X-ray findings in patients with RA.

The FINCH series of clinical trials, which included FINCH 1, FINCH 2, and FINCH 3, provided robust data on the efficacy of filgotinib. In these studies, filgotinib was compared with placebo and, in some cases, with other active treatments. The results consistently demonstrated that patients treated with Jyseleca experienced greater improvements in the American College of Rheumatology (ACR) criteria, which measure the reduction of RA symptoms, compared to those who received placebo or a comparator drug.

Rinvoq (upadacitinib) Efficacy in Rheumatoid Arthritis

Rinvoq, with the generic name upadacitinib, is another JAK inhibitor that has been approved for the treatment of moderate to severe rheumatoid arthritis in adult patients who have had an inadequate response or intolerance to methotrexate. Upadacitinib selectively inhibits JAK1, which is implicated in the pathophysiology of RA. Clinical trials have shown that Rinvoq is effective in reducing the signs and symptoms of RA, achieving clinical remission, and improving physical function in the target patient population.

The SELECT series of phase 3 trials, including SELECT-NEXT, SELECT-BEYOND, SELECT-COMPARE, and SELECT-MONOTHERAPY, have provided evidence of upadacitinib's efficacy. These studies have shown that patients taking Rinvoq had a higher rate of ACR response compared to those on placebo or other DMARDs. Additionally, upadacitinib was found to slow the progression of joint damage, which is a critical aspect of managing RA over the long term. The SELECT-COMPARE trial, in particular, demonstrated the superiority of upadacitinib over adalimumab, a TNF inhibitor, when both were combined with methotrexate, in patients who did not respond adequately to methotrexate alone.